Carcinoma of gallbladder and extrahepatic biliary tract

disease
On this page

Also known as carcinoma of gallbladder and EBT

Summary

Carcinoma of gallbladder and extrahepatic biliary tract (MONDO:0018918) is a cancer with 1 GWAS associations across 4 studies. A subtype of extrahepatic bile duct neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Prevalence: 1-5 / 10 000 (Worldwide) [Orphanet-validated]
  • GWAS associations: 1

Clinical features

Epidemiology

Prevalence records

7 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Annual incidence1-5 / 10 00012WorldwideValidated
Annual incidence1-9 / 100 0004.37EuropeValidated
Annual incidence1-5 / 10 00014PolandValidated
Point prevalence1-5 / 10 000EuropeNot yet validated
Annual incidence1-9 / 100 0005.3JapanNot yet validated
Annual incidence1-9 / 100 0001.5United StatesNot yet validated
Annual incidence1-9 / 100 0001.27FranceNot yet validated

Identifiers

Disease identifiers

FieldValue
Canonical namecarcinoma of gallbladder and extrahepatic biliary tract
Mondo IDMONDO:0018918
Orphanet56044
UMLSC5566557
MedGen1797980
GARD0018850
MedDRA10007426
Is cancer (heuristic)yes

Also known as: carcinoma of gallbladder and EBT

Data availability: 1 GWAS association (4 studies) · 97 cell lines.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorderhepatobiliary disorderbiliary tract disorderbile duct disorderbile duct neoplasm › extrahepatic bile duct neoplasm › carcinoma of gallbladder and extrahepatic biliary tract

Related subtypes (6): extrahepatic bile duct lipoma, extrahepatic bile duct leiomyoma, extrahepatic bile duct adenoma, common bile duct neoplasm, gallbladder neuroendocrine tumor, grade 1/2, malignant tumor of extrahepatic bile duct

Subtypes (2): adenocarcinoma of gallbladder and extrahepatic biliary tract, squamous cell carcinoma of gallbladder and extrahepatic biliary tract

Genetics & variants

GWAS landscape

1 GWAS associations across 4 studies. Top hits map to 2 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs1811705031e-09PSG2, PSG11-AS1?

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90481490Verma A2024471450,748Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651316Liu TY2025223211,360Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90435586Zhou W2018196393,372Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90041817Jiang L2021195456,153A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic1

MAF distribution

BucketVariants
common (>=0.05)0
low_freq (0.01-0.05)0
rare (<0.01)0
unknown1

Functional consequences

ConsequenceCount
intron_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs1811705031943074284G>Cintron_variantPSG2, PSG11-AS11e-09Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.